Carregando...
Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
Agents inhibiting the phosphoinositide 3–kinase–Akt–mammalian target of rapamycin (PAM) pathway are currently in various stages of clinical development in oncology, ranging from some in early-phase evaluations to others that have already received regulatory approval for treatment in advanced cancers...
Na minha lista:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Clinical Oncology
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3410405/ https://ncbi.nlm.nih.gov/pubmed/22778315 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.39.7356 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|